While we observe many similarities in the transcriptional profiles between these two diseases, the genes that are dysregulated in opposite directions might provide therapeutic targets and biomarkers– centered around turning AML-ASXL1 profile closer to that seen in BOS blood, thereby ameliorating the malignant potential. The gene discussed is ASXL1; the disease is acute myeloid leukemia.